CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.
CIViC Variants/p16 Expression

p16 Expression

CIViC ID: 272 · Gene: CDKN2A

Variant Summary

HGVS
—
Variant Type(s)
—
Evidence Items
10

Evidence Level Distribution

Level A: 1Level B: 9

Evidence Items

Showing CIViC evidence rows where gene = CDKN2A and variant = p16 Expression.

LevelTypeDirectionSignificanceDiseaseDrugsRating
BPrognosticSupportsBetter OutcomeHead And Neck Squamous Cell Carcinoma4
BPredictiveDoes Not SupportResistanceHead And Neck Squamous Cell CarcinomaCetuximab4
APrognosticSupportsBetter OutcomeOropharynx Cancer4
BPredictiveDoes Not SupportResistanceOropharynx CancerCetuximab4
BPredictiveDoes Not SupportResistanceHead And Neck Squamous Cell CarcinomaEpidermal Growth Factor Receptor Tyrosine Kinase Inhibitor3
BPredictiveSupportsResistanceHead And Neck Squamous Cell CarcinomaPanitumumab3
BPredictiveSupportsSensitivity/ResponseHead And Neck Squamous Cell CarcinomaPanitumumab3
BPrognosticSupportsBetter OutcomeHead And Neck Squamous Cell Carcinoma3
BPredictiveSupportsResistanceHead And Neck Squamous Cell CarcinomaAfatinib2
BPrognosticSupportsPoor OutcomeLung Non-small Cell Carcinoma2